- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
New Blood Pump System Approved
The Impella 2.5 System has been approved by the U.S. Food and Drug Administration to maintain stable heart function and blood circulation during high-risk cardiac operations, the agency said in a news release.
The miniature blood pump is sanctioned for coronary artery disease patients during higher-risk procedures such as angioplasty, when a blocked artery is unclogged using an inflated balloon, the agency said.
The system is guided into the left ventricle of the heart via a catheter that’s typically inserted into a leg vein. An external controller and monitor turns the pump on and off, measures heart function and allows doctors to adjust the pump as needed, the FDA said.
People with coronary artery disease commonly have diminished blood flow to the heart, which could lead to serious complications during surgery, the agency said.
The Impella System is produced by Abiomed Inc., based in Danvers, Mass.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.